{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:48:08Z","timestamp":1793638088730,"version":"4.5.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC 82560096"],"award-info":[{"award-number":["NSFC 82560096"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20224BAB216018"],"award-info":[{"award-number":["20224BAB216018"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20232BAB206013"],"award-info":[{"award-number":["20232BAB206013"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20232BAB216009"],"award-info":[{"award-number":["20232BAB216009"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022957","name":"Double Thousand Plan of Jiangxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.metabol.2026.156594","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T06:20:30Z","timestamp":1773728430000},"page":"156594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives"],"prefix":"10.1016","volume":"179","author":[{"given":"Linghua","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaosi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.metabol.2026.156594_bb0005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.metabol.2026.156594_bb0010","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.eprac.2025.07.017","article-title":"American Association of Clinical Endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity\/adiposity-based chronic disease - 2025 update","volume":"31","author":"Nadolsky","year":"2025","journal-title":"Endocr Pract"},{"key":"10.1016\/j.metabol.2026.156594_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156303","article-title":"Exploring the interplay of genetic variants and environmental factors in childhood obesity: a systematic review and meta-analysis","volume":"170","author":"Zhu","year":"2025","journal-title":"Metabolism"},{"issue":"10481","key":"10.1016\/j.metabol.2026.156594_bb0020","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","year":"2025","journal-title":"Lancet"},{"issue":"10440","key":"10.1016\/j.metabol.2026.156594_bb0025","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","article-title":"Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156594_bb0030","series-title":"World Obesity Atlas","volume":"2025","author":"World Obesity Federation","year":"2025"},{"issue":"22","key":"10.1016\/j.metabol.2026.156594_bb0035","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1001\/jama.2016.7602","article-title":"Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis","volume":"315","author":"Khera","year":"2016","journal-title":"Jama"},{"issue":"15","key":"10.1016\/j.metabol.2026.156594_bb0040","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1016\/j.cell.2024.06.003","article-title":"Transforming obesity: the advancement of multi-receptor drugs","volume":"187","author":"Kusminski","year":"2024","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.metabol.2026.156594_bb0045","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1056\/NEJMcibr2409089","article-title":"Discovery of GLP-1-based drugs for the treatment of obesity","volume":"392","author":"Drucker","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.metabol.2026.156594_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"10148","key":"10.1016\/j.metabol.2026.156594_bb0055","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.metabol.2026.156594_bb0060","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.metabol.2026.156594_bb0065","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.metabol.2026.156594_bb0070","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJMoa2500969","article-title":"Oral semaglutide at a dose of 25 mg in adults with overweight or obesity","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"issue":"10434","key":"10.1016\/j.metabol.2026.156594_bb0075","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S0140-6736(24)00351-9","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"403","author":"Shi","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.metabol.2026.156594_bb0080","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.metabol.2026.156594_bb0085","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156594_bb0090","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejim.2025.02.022","article-title":"Glucagon-like peptide-1 receptor agonist for patients with heart failure with preserved ejection fraction and obesity","volume":"137","author":"Fu","year":"2025","journal-title":"Eur J Intern Med"},{"issue":"2","key":"10.1016\/j.metabol.2026.156594_bb0095","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.metabol.2026.156594_bb0100","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.metabol.2026.156594_bb0105","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156594_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156463","article-title":"Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials","volume":"175","author":"Karakasis","year":"2026","journal-title":"Metabolism"},{"issue":"16","key":"10.1016\/j.metabol.2026.156594_bb0115","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.124.067676","article-title":"Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or maladaptive response to weight loss?","volume":"150","author":"Linge","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.metabol.2026.156594_bb0120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.metabol.2026.156594_bb0125","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.metabol.2026.156594_bb0130","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","article-title":"Once-weekly mazdutide in Chinese adults with obesity or overweight","volume":"392","author":"Ji","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.metabol.2026.156594_bb0135","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"10499","key":"10.1016\/j.metabol.2026.156594_bb0140","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(25)01176-6","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial","volume":"406","author":"Gasiorek","year":"2025","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.metabol.2026.156594_bb0145","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1016\/j.cell.2025.06.010","article-title":"Brain control of energy homeostasis: implications for anti-obesity pharmacotherapy","volume":"188","author":"Johansen","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2026.156594_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107987","article-title":"Salmon calcitonin distributes into the arcuate nucleus to a subset of NPY neurons in mice","volume":"167","author":"Zakariassen","year":"2020","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.metabol.2026.156594_bb0155","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tem.2024.05.002","article-title":"Neuroendocrine gut-brain signaling in obesity","volume":"36","author":"Gruber","year":"2025","journal-title":"Trends Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2026.156594_bb0160","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.cmet.2015.09.026","article-title":"Neuronal regulation of energy homeostasis: beyond the hypothalamus and feeding","volume":"22","author":"Waterson","year":"2015","journal-title":"Cell Metab"},{"issue":"6741","key":"10.1016\/j.metabol.2026.156594_bb0165","doi-asserted-by":"crossref","DOI":"10.1126\/science.adt0773","article-title":"Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety","volume":"387","author":"Zhu","year":"2025","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.metabol.2026.156594_bb0170","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/HEP.0000000000000735","article-title":"Metabolic dysfunction-associated steatotic liver disease and the heart","volume":"82","author":"Driessen","year":"2025","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.metabol.2026.156594_bb0175","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41574-025-01125-9","article-title":"Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus","volume":"21","author":"Walker","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"6587","key":"10.1016\/j.metabol.2026.156594_bb0180","doi-asserted-by":"crossref","DOI":"10.1126\/science.abm9609","article-title":"A structural basis for amylin receptor phenotype","volume":"375","author":"Cao","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.metabol.2026.156594_bb0185","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3389\/fendo.2017.00324","article-title":"Involvement of amylin and leptin in the development of projections from the area postrema to the nucleus of the solitary tract","volume":"8","author":"Abegg","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10.1016\/j.metabol.2026.156594_bb0190","doi-asserted-by":"crossref","first-page":"E562","DOI":"10.1152\/ajpendo.2001.280.4.E562","article-title":"Evidence that amylin stimulates lipolysis in vivo: a possible mediator of induced insulin resistance","volume":"280","author":"Ye","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2026.156594_bb0195","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.regpep.2006.06.004","article-title":"Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187","volume":"137","author":"Gedulin","year":"2006","journal-title":"Regul Pept"},{"issue":"2\u20133","key":"10.1016\/j.metabol.2026.156594_bb0200","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0167-4889(95)00033-O","article-title":"Dose-dependent elevation of cyclic AMP, activation of glycogen phosphorylase, and release of lactate by amylin in rat skeletal muscle","volume":"1267","author":"Pittner","year":"1995","journal-title":"Biochim Biophys Acta"},{"issue":"20","key":"10.1016\/j.metabol.2026.156594_bb0205","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1073\/pnas.0706473105","article-title":"Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies","volume":"105","author":"Roth","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"52","key":"10.1016\/j.metabol.2026.156594_bb0210","doi-asserted-by":"crossref","first-page":"52810","DOI":"10.1074\/jbc.M308244200","article-title":"Fibrillogenic amylin evokes islet beta-cell apoptosis through linked activation of a caspase cascade and JNK1","volume":"278","author":"Zhang","year":"2003","journal-title":"J Biol Chem"},{"issue":"23","key":"10.1016\/j.metabol.2026.156594_bb0215","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1073\/pnas.84.23.8628","article-title":"Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients","volume":"84","author":"Cooper","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.metabol.2026.156594_bb0220","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/BF00401833","article-title":"Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin","volume":"38","author":"Young","year":"1995","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.metabol.2026.156594_bb0225","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/oby.2004.76","article-title":"Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients","volume":"12","author":"Hollander","year":"2004","journal-title":"Obes Res"},{"issue":"3","key":"10.1016\/j.metabol.2026.156594_bb0230","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1016\/j.metabol.2026.156594_bb0235","doi-asserted-by":"crossref","first-page":"11183","DOI":"10.1021\/acs.jmedchem.1c00565","article-title":"Development of cagrilintide, a long-acting amylin analogue","volume":"64","author":"Kruse","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.metabol.2026.156594_bb0240","article-title":"A cross-species atlas of the dorsal vagal complex reveals neural mediators of cagrilintide\u2019s effects on energy balance","author":"Ludwig","year":"2025","journal-title":"bioRxiv"},{"issue":"4","key":"10.1016\/j.metabol.2026.156594_bb0245","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s42255-021-00363-1","article-title":"A genetic map of the mouse dorsal vagal complex and its role in obesity","volume":"3","author":"Ludwig","year":"2021","journal-title":"Nat Metab"},{"issue":"10317","key":"10.1016\/j.metabol.2026.156594_bb0250","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.metabol.2026.156594_bb0255","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N Engl J Med"},{"issue":"10499","key":"10.1016\/j.metabol.2026.156594_bb0260","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(25)01250-4","article-title":"GLP-1 and amylin receptor multiagonism with amycretin for obesity management","volume":"406","author":"Khoo","year":"2025","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.metabol.2026.156594_bb0265","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s42255-025-01324-8","article-title":"CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure","volume":"7","author":"Jacobsen","year":"2025","journal-title":"Nat Metab"},{"issue":"10286","key":"10.1016\/j.metabol.2026.156594_bb0270","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"issue":"10403","key":"10.1016\/j.metabol.2026.156594_bb0275","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.metabol.2026.156594_bb0280","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes","volume":"393","author":"Davies","year":"2025","journal-title":"N Engl J Med"},{"issue":"10499","key":"10.1016\/j.metabol.2026.156594_bb0285","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0140-6736(25)01185-7","article-title":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b\/2a randomised controlled study","volume":"406","author":"Dahl","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156594_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105862","article-title":"The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats","volume":"118","author":"Kuhre","year":"2025","journal-title":"EBioMedicine"},{"issue":"467","key":"10.1016\/j.metabol.2026.156594_bb0295","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci Transl Med"},{"issue":"10403","key":"10.1016\/j.metabol.2026.156594_bb0300","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.metabol.2026.156594_bb0305","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily Oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.metabol.2026.156594_bb0310","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"10520","key":"10.1016\/j.metabol.2026.156594_bb0315","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/S0140-6736(25)02155-5","article-title":"Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial","volume":"406","author":"Billings","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156594_bb0320","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","volume":"385","author":"Simms-Williams","year":"2024","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.metabol.2026.156594_bb0325","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40262-019-00756-2","article-title":"Effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin in healthy subjects","volume":"58","author":"B\u00e6kdal","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.metabol.2026.156594_bb0330","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet Med"},{"issue":"6","key":"10.1016\/j.metabol.2026.156594_bb0335","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/CIRCRESAHA.116.305697","article-title":"Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms","volume":"116","author":"Hall","year":"2015","journal-title":"Circ Res"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526001046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526001046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:13:24Z","timestamp":1779164004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049526001046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":67,"alternative-id":["S0026049526001046"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156594","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156594","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156594"}}